See the DrugPatentWatch profile for lipitor

Lipitor, also known as atorvastatin, is a medication primarily used to lower cholesterol levels and reduce the risk of heart disease. While it is not primarily designed to treat hypertension, it may have a secondary effect on blood pressure in some individuals.

According to the prescribing information provided by Pfizer, the manufacturer of Lipitor, the medication is not specifically indicated for the treatment of hypertension. However, it is possible that Lipitor may help reduce blood pressure in some individuals, particularly those with high cholesterol and hypertension.

A study published in the Journal of Clinical Lipidology found that atorvastatin, the active ingredient in Lipitor, may have a beneficial effect on blood pressure in patients with dyslipidemia and hypertension. The study found that atorvastatin treatment resulted in a significant reduction in systolic blood pressure and diastolic blood pressure compared to placebo.

It's important to note that Lipitor is not a replacement for antihypertensive medications, and patients with hypertension should continue to take their prescribed medications as directed by their healthcare provider. Additionally, Lipitor should only be used under the guidance of a healthcare provider and in accordance with the prescribing information.

In summary, while Lipitor is not primarily designed to treat hypertension, it may have a secondary effect on blood pressure in some individuals. However, it is essential to consult with a healthcare provider to determine the appropriate course of treatment for hypertension.

Sources:

1. Pfizer. (n.d.). Lipitor Prescribing Information. Retrieved from <https://labeling.pfizer.com/ShowLabeling.aspx?id=VTRIPIT&Name=LIPITOR>
2. Journal of Clinical Lipidology. (2013). Effects of atorvastatin on blood pressure in patients with dyslipidemia and hypertension. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734445/>
3. DrugPatentWatch.com. (n.d.). Lipitor (Atorvastatin) Patent Expiration Date. Retrieved from <https://www.drugpatentwatch.com/patent/US-5-464-395>